Zobrazeno 1 - 10
of 41
pro vyhledávání: '"E, Salewski"'
Publikováno v:
Scandinavian Journal of Infectious Diseases. 30:397-404
A multinational, multicentre, open, randomised study in hospitalised patients with pneumonia compared levofloxacin 500 mg twice daily with ceftriaxone 4 g i.v. once daily. Levofloxacin patients started on i.v. treatment and switched to oral on d 3-5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e58b20e080aeb8749b017e33884418e6
https://doi.org/10.1080/00365549850160710
https://doi.org/10.1080/00365549850160710
Publikováno v:
Cancer. 66:651-654
Thirty-five non-pretreated patients (29 male, six female) with malignant pleural mesothelioma, median age of 68.5 years (range, 29 to 78 years) and a median performance status of 80% (range, 60% to 100%) were treated with 70 mg/m2 Pirarubicin. The tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6f3807c1c657c4fc7107482279f707fd
https://doi.org/10.1002/1097-0142(19900815)66:4<651::aid-cncr2820660408>3.0.co
https://doi.org/10.1002/1097-0142(19900815)66:4<651::aid-cncr2820660408>3.0.co
Publikováno v:
Oncology Research and Treatment. 13:180-184
Forty-seven patients with advanced non-small cell lung cancer (NSCLC) were treated in a multicentre phase II study with pirarubicin (THP), 4’-O-tetrahydropyranyl-doxorubicin using a dosage of 70mg/ m2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d73584cb1f7e8df4a5a5d21ce56ccc31
https://doi.org/10.1159/000216754
https://doi.org/10.1159/000216754
Autor:
Lucka Tos, Raul Raz, M. Milicevic, P. Bassaris, J. Kosmidis, H. Noack, A. Tourkantonis, E. Akalin, M. Sukalo, Ruth Kitzes, E. Salewski, Semra Calangu
Publikováno v:
Infection. 23(4)
In a multinational, open, randomised, controlled clinical study, 474 hospitalised patients with moderate or severe infections were treated with sequential regimens of ofloxacin or ciprofloxacin. Ofloxacin 400 mg once daily or ciprofloxacin 200 mg twi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dea279b2ee8af3dc628aa2809aa2bcfc
https://pubmed.ncbi.nlm.nih.gov/8522381
https://pubmed.ncbi.nlm.nih.gov/8522381
Publikováno v:
Cancer. 66(4)
Thirty-five non-pretreated patients (29 male, six female) with malignant pleural mesothelioma, median age of 68.5 years (range, 29 to 78 years) and a median performance status of 80% (range, 60% to 100%) were treated with 70 mg/m2 Pirarubicin. The tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c3a4d26535b93df483a7a984c3015c09
https://pubmed.ncbi.nlm.nih.gov/2386894
https://pubmed.ncbi.nlm.nih.gov/2386894
Autor:
U. Essers, Lutz Edler, H.-E. Wander, Heinz H. Fiebig, B. Greifenberg, E. Salewski, Ulrich R. Kleeberg, Jörg Beyer, L. Reichel
Publikováno v:
Onkologie. 13(3)
Pirarubicin is a more lipophilic derivative of doxorubicin, with a higher uptake rate of cells, lower cardiotoxicity and better antitumor efficacy in preclinical models. Thirty-four patients with metastatic breast cancer were treated in a multicenter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1896565f80a64c533fefdc68a695b6a4
https://pubmed.ncbi.nlm.nih.gov/2204003
https://pubmed.ncbi.nlm.nih.gov/2204003
Publikováno v:
Onkologie. 13(3)
Forty-seven patients with advanced non-small cell lung cancer (NSCLC) were treated in a multicentre phase II study with pirarubicin (THP), 4'-O-tetrahydropyranyl-doxorubicin using a dosage of 70 mg/m2 every 3 weeks. The median age of the patients was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d024fe7bbad6ca626d96362d1172ff37
https://pubmed.ncbi.nlm.nih.gov/2168533
https://pubmed.ncbi.nlm.nih.gov/2168533
Autor:
Gabriel N. Hortobagyi, E. Salewski, Jungsil Ro, Ronald S. Walters, Richard L. Theriault, Charles K. Tashima, Debra Frye, Giuseppe Fraschini, Aman U. Buzdar
Publikováno v:
American journal of clinical oncology. 13
Pirarubicin is an anthracycline with broad antitumor activity, and without significant cardiotoxicity in preclinical and early clinical trials. We treated 40 evaluable patients with metastatic breast cancer and no prior exposure to chemotherapy with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98b14cfe9591e7401c08dabc13cab001
https://pubmed.ncbi.nlm.nih.gov/2291460
https://pubmed.ncbi.nlm.nih.gov/2291460
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Cancer Therapy ISBN: 9783642737237
The widespread use of doxorubicin in cancer treatment has prompted studies of compounds with similar structures. Preferably, such new compounds should retain or exceed the activity of doxorubicin but have fever of its toxic side effects. Activity in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::69a91c0e26f34572268d212ce1841852
https://doi.org/10.1007/978-3-642-73721-3_30
https://doi.org/10.1007/978-3-642-73721-3_30
